Skip to main content
. 2019 May 28;10(37):3472–3490. doi: 10.18632/oncotarget.26930

Table 1. Complete blood count: Values are expressed as mean ± SD (n = 8).

Parameters Group I Group II Group III Group IV
PVC 39.33 ± 0.67 35.20 ± 1.93 37.25 ± 3.04 33.75 ± 0.25
White blood cells (10 m/m3) 6500 ± 288.68 6100 ± 556.78 6500 ± 540.06 5000 ± 204.12
Lymphocytes 18.23 ± 1.76 20.00 ± 0.50* 20.40 ± 0.58 20.00 ± 0.82
Neutrophils 81.67 ± 1.76 78.20 ± 0.58* 79.50 ± 0.96 79.00 ± 0.86
Hb (g/dl) 8.10 ± 0.29 6.07 ± 0.18 6.93 ± 0.26 7.10 ± 0.70
MCV(μm3) 72.9 ± 7.97 133.4 ± 23 105.7 ± 15.6 88.0 ± 10.2
MCH (pg) 20.9 ± 2.21 31.1 ± 4.37 26.7 ± 4.04 22.7 ± 1.75
MCHC (%) 29.1 ± 1.88 24.1 ± 1.74 25.9 ± 2.31 26.7 ± 1.98
RBC (106 /mm3) 8.67 ± 0.072 6.40 ± 0.092* 7.47 ± 0.0821** 8.52 ± 0.079

Group I: Normal control treated with saline (0.9%); Group II: Hepatotoxic control group treated with acetaminophen (750 mg/kg body weight); Group III: Treated with FEO (250 mg/kg body weight) and acetaminophen (750 mg/kg body weight); Group IV: Treated with FEO (500 mg/kg body weight) and acetaminophen (750 mg/kg body weight). *Represents significant difference at P < 0.05 compared with control. **Represents significant difference at P < 0.01 compared with hepatotoxic control group.